Helixgate

Helixgate

Uncategorized

Bioprocessing Applications Laboratory Opened in Korea by Ecolab Life Sciences

Published

on

Officials at Ecolab Life Sciences report that the company is expanding its bioprocessing business with the launch of a new bioprocessing applications lab (BPAL) in Dongtan, Korea. They say the goal is to provide biopharmaceutical manufacturers across Asia with better local access to downstream process development support.

The site is Ecolab’s first bioprocessing facility in Asia and joins an established applications network in the U.S. and U.K.

BPAL Korea supports process development from early-stage resin screening through studies designed to replicate commercial manufacturing conditions, according to Jenny Tan, vice president and general manager, Ecolab Life Sciences APAC and India. On-site scientists work alongside customers across Asia to help optimize chromatography steps, improve yield and productivity, and accelerate regulatory pathways, with the aim of reducing the need to ship resins and reference materials overseas for development work, she continues.

Asia has become one of the world’s most active biopharmaceutical manufacturing regions, with Korea, China, Japan, India, and Singapore all home to growing pipelines in biosimilars and monoclonal antibody processes that scalable downstream purification. With local technical support now in place, manufacturers across the region can shorten development cycles and maintain consistency with global operations while working to tight regulatory and cost targets, continues Tan.

“Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations,” she explains. “BPAL Korea strengthens our ability to work side by side with customers, bringing local expertise together with Ecolab’s global, integrated bioprocessing network.”

By combining local scientific support with Ecolab’s innovative Purolite™ resin portfolio, Ecolab’s new BPAL was created to help enable manufacturers to address process challenges earlier, reduce development risk, and advance programs with greater confidence as they prepare for scaleup, says Tan.

The post Bioprocessing Applications Laboratory Opened in Korea by Ecolab Life Sciences appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise

XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise

Published

on

Plus, news about PCI Pharma:

🏭 XTL Bio steps into psychedelics: XTL Biopharmaceuticals is acquiring 100% of the outstanding shares of psychedelic-focused biotech Psyga Bio. XTL will gain Psyga’s manufacturing facility …​ ​Read More

Continue Reading

Uncategorized

STAT+: Cigna will exit ACA individual markets next year, adding to tumult for patients

Cigna is pulling out of the Affordable Care Act’s individual marketplaces in 2027 to focus on more promising parts of its business, another exit from what’s become a tumultuous piece of the insurance industry. 

Executives announced the decision on Cigna’s first quarter earnings call on Thursday, in which the company unveiled better-than-expected financial results, including $1.7 billion in profit, and a bumped-up earnings forecast for the year. Cigna currently has 369,000 ACA members across 11 states, a small portion of its 18.3 million total members.

Brian Evanko, Cigna’s chief operating officer, said on the call that Cigna did not take the decision lightly. He said it was driven by two main factors: Cigna did not see a way to meaningfully grow that business and cutting it would free Cigna to focus on priorities like its Evernorth specialty and care services division, its pharmacy benefits division, and its flagship employer plan business. 

Continue to STAT+ to read the full story…

Read More

Published

on

Cigna is pulling out of the Affordable Care Act’s individual marketplaces in 2027 to focus on more promising parts of its business, another exit from what’s become a tumultuous piece of the insurance industry. 

Executives announced the decision on Cigna’s first quarter earnings call on Thursday, in which the company unveiled better-than-expected financial results, including $1.7 billion in profit, and a bumped-up earnings forecast for the year. Cigna currently has 369,000 ACA members across 11 states, a small portion of its 18.3 million total members.

Brian Evanko, Cigna’s chief operating officer, said on the call that Cigna did not take the decision lightly. He said it was driven by two main factors: Cigna did not see a way to meaningfully grow that business and cutting it would free Cigna to focus on priorities like its Evernorth specialty and care services division, its pharmacy benefits division, and its flagship employer plan business. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel

Published

on

UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing a 75% slowing of disease—the same data the FDA has deemed unacceptable for a biologics license application.

Continue Reading
Advertisement

Trending